Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 2
2012 1
2013 1
2017 2
2018 2
2019 1
2020 1
2021 3
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Hepatic glucagon action: beyond glucose mobilization.
Kajani S, Laker RC, Ratkova E, Will S, Rhodes CJ. Kajani S, et al. Among authors: will s. Physiol Rev. 2024 Jul 1;104(3):1021-1060. doi: 10.1152/physrev.00028.2023. Epub 2024 Feb 1. Physiol Rev. 2024. PMID: 38300523 Review.
Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries.
Boland BB, Laker RC, O'Brien S, Sitaula S, Sermadiras I, Nielsen JC, Barkholt P, Roostalu U, Hecksher-Sørensen J, Sejthen SR, Thorbek DD, Suckow A, Burmeister N, Oldham S, Will S, Howard VG, Gill BM, Newton P, Naylor J, Hornigold DC, Austin J, Lantier L, McGuinness OP, Trevaskis JL, Grimsby JS, Rhodes CJ. Boland BB, et al. Among authors: will s. Mol Metab. 2022 Jan;55:101392. doi: 10.1016/j.molmet.2021.101392. Epub 2021 Nov 12. Mol Metab. 2022. PMID: 34781035 Free PMC article.
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF. Artis DR, et al. Among authors: will s. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30. Proc Natl Acad Sci U S A. 2009. PMID: 19116277 Free PMC article.
Applying RE-AIM to examine the impact of an implementation facilitation package to scale up a program for Veterans with Chronic Obstructive Pulmonary Disease.
Portillo EC, Maurer MA, Kettner JT, Bhardwaj SD, Zhang Z, Sedgwick C, Gilson AM, Stone JA, Jacobson N, Hennessy-Garza R, Will S, McFarland MS, Ourth H, Chui MA. Portillo EC, et al. Among authors: will s. Res Sq [Preprint]. 2023 Jun 8:rs.3.rs-2809287. doi: 10.21203/rs.3.rs-2809287/v1. Res Sq. 2023. PMID: 37333195 Free PMC article. Updated. Preprint.
Systems Biology and Peptide Engineering to Overcome Absorption Barriers for Oral Peptide Delivery: Dosage Form Optimization Case Study Preceding Clinical Translation.
Tyagi P, Patel C, Gibson K, MacDougall F, Pechenov SY, Will S, Revell J, Huang Y, Rosenbaum AI, Balic K, Maharoof U, Grimsby J, Subramony JA. Tyagi P, et al. Among authors: will s. Pharmaceutics. 2023 Oct 9;15(10):2436. doi: 10.3390/pharmaceutics15102436. Pharmaceutics. 2023. PMID: 37896196 Free PMC article.
Applying RE-AIM to examine the impact of an implementation facilitation package to scale up a program for Veterans with chronic obstructive pulmonary disease.
Portillo EC, Maurer MA, Kettner JT, Bhardwaj SD, Zhang Z, Sedgwick C, Gilson AM, Stone JA, Jacobson N, Hennessy-Garza R, Will S, McFarland MS, Ourth H, Chui MA. Portillo EC, et al. Among authors: will s. Implement Sci Commun. 2023 Nov 21;4(1):143. doi: 10.1186/s43058-023-00520-5. Implement Sci Commun. 2023. PMID: 37990241 Free PMC article.
18 results